Market cap
₹35 Cr
Recently Viewed
Clear AllBSE: 524661
₹0.28
₹0.00 (0.00%)As on 30-Apr-2026IST
Market cap
₹35 Cr
Revenue (TTM)
₹387 Cr
P/E Ratio
1
P/B Ratio
0.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹35 Cr
ROE
4.2 %
ROCE
2.5 %
Industry P/E
45.99
EV/EBITDA
3.4
Debt to Equity
1.2
Book Value
₹1.2
EPS
₹2.4
Face value
1
Shares outstanding
1,235,940,230
CFO
₹-222.04 Cr
EBITDA
₹0.71 Cr
Net Profit
₹2.26 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Welcure Drugs
| -33.3 | 12.0 | -12.5 | -66.3 | -8.9 | 8.4 | 7.8 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Welcure Drugs
| -58.3 | 195.4 | -31.0 | -26.2 | 234.6 | 353.1 | -5.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Welcure Drugs
|
0.3 | 34.6 | 386.8 | 35.4 | 11.1 | 29.9 | 1 | 0.2 |
| 1,216.4 | 5,311.2 | 6,020.3 | 132.1 | 3.2 | 6.8 | 47.1 | 3.0 | |
| 35.9 | 15.8 | 25.3 | 0.1 | 0.4 | 2.5 | 138.6 | 3.3 | |
| 28.1 | 35.1 | 16.0 | -4.4 | -58.4 | -3.7 | -- | 0.3 | |
| 21.9 | 31.1 | 49.7 | 4.1 | -- | 29.1 | 7.5 | 1.5 | |
| 41.9 | 26.3 | 4.6 | 0.4 | 1.7 | 4 | 67.3 | 2.6 | |
| 45.4 | 24.8 | 294.6 | 2.1 | 0.9 | 163.8 | 12.1 | 9.8 | |
| 330.5 | 290.3 | 58.3 | 8.6 | -- | 37.9 | 33.7 | 4.9 | |
| 109.3 | 213.4 | 106.8 | 4.8 | -- | 14.9 | 44.5 | 5.7 | |
| 2.1 | 8.3 | 110.0 | -0.2 | 0.0 | -3.5 | -- | 1.7 |
No Review & Analysis are available.
Welcure Drugs & Pharmaceuticals Limited engages in the wholesale of pharmaceutical and medical goods in India. The company was incorporated in 1996 and is based in Delhi, India.
Incorporated
1996
Chairman
--
Managing Director
Chintan Didawala
Headquarters
Delhi, Delhi
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Welcure Drugs & Pharmaceuticals Ltd is ₹0.28 (BSE) as of 30-Apr-2026 IST. Welcure Drugs & Pharmaceuticals Ltd has given a return of -8.95% in the last 3 years.
The P/E ratio of Welcure Drugs & Pharmaceuticals Ltd is 0.98 times as on 30-Apr-2026, a 98 discount to its peers’ median range of 45.99 times.
The P/B ratio of Welcure Drugs & Pharmaceuticals Ltd is 0.24 times as on 30-Apr-2026, a 20 discount to its peers’ median range of 0.30 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
4.28
|
1.00
|
|
2024
|
0.00
|
3.77
|
|
2023
|
52.97
|
3.57
|
|
2022
|
501.03
|
127.31
|
|
2021
|
41.32
|
32.82
|
The 52-week high and low of Welcure Drugs & Pharmaceuticals Ltd are Rs 1.44 and Rs 0.23 as of 30-Apr-2026.
Welcure Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹ 35 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Welcure Drugs & Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.